Ameritox Study on ADHD Medication Behavior in Adolescents Reveals Which Drug is More Likely to be Misused or Diverted

Wednesday, November 2, 2016 Drug News
Email Print This Page Comment bookmark
Font : A-A+

Ameritox's Ingenuity Health Committed to Finding Sub-trends That Will Help Doctors Better Treat and Protect Their Patients

BALTIMORE, Nov. 2, 2016 /PRNewswire/ -- Ingenuity Health, a leading provider of medication monitoring solutions to behavioral

health clinicians and a service of AmeritoxSM, today released research showing that patients between the ages of 6 and 25 who are prescribed medication to treat Attention Deficit Hyperactivity Disorder (ADHD) were more likely to test negative for a prescribed amphetamine medication than a prescribed methylphenidate.

More than 35 percent of patients tested negative for a prescribed amphetamine, compared with just over 26 percent of those who tested negative for prescribed methylphenidate. The research outcomes are based on urine samples collected from patients over a 16-month period.  

"Our research confirmed the ongoing problem of adolescents not taking their prescribed ADHD medication properly with almost 33 percent of the patients testing negative for the prescribed medication," said Ameritox Chief Medical Officer Thomas Smith, MD.  "Interestingly, the study also suggests that the amphetamine drugs are more likely to be misused or diverted than methylphenidate."

"One hypothesis in the treating community is that amphetamine– a drug which is highly effective for ADHD – is also more likely to be diverted to the street or shared with friends," Smith continued. "While our study does not provide proof that this is the case, it does support the hypothesis."

"When we begin a study, we seek to either confirm or deny a broad trend within medical research, but we also want to dive down into sub-trends that will help the doctors we serve to better understand their patients, and protect them from dangerous behavior," said Scott Walton, Ameritox CEO. "This research shows our commitment to isolating the troubling behavior that can lead to poor patient outcomes and potential human tragedy, and to providing clinicians the added knowledge to help prevent it."

The Ameritox Medical Affairs team this week presented this research in the form of a medical poster titled "Medication Adherence in Pediatric and Young Adult Patients Prescribed ADHD Stimulant Medications" to the American Academy of Child and Adolescent Psychiatry conference, held in New York. For more information on this conference, please visit:

About Ameritox Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: Follow Ingenuity Health on Twitter:

About Ingenuity Health As part of AmeritoxSM, a national leader in medication monitoring solutions, Ingenuity Health utilizes urine drug monitoring to provide highly reliable data and analysis that helps doctors and behavioral health specialists better treat patients diagnosed with serious mental illness (SMI).

Visit the Ingenuity Health website at: Follow Ingenuity Health on Twitter:


Contact: Genevieve Rozansky 30 Point Strategies 202-509-0794

To view the original version on PR Newswire, visit:

SOURCE Ameritox


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store